Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based doublet chemotherapy.

Trial Details

NCT ID
NCT06659042
Phase
PHASE2
Sponsor
Shanghai Chest Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Tislelizumab
  • Cisplatin
  • Carboplatin
  • Pemetrexed Disodium
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Able to provide written informed consent (ICF) and able to understand and comply with the study requirements and assessment schedule.
  • Male or female aged ≥18 years at the time of signing the ICF.
  • Histologically or cytologically confirmed stage II-IIIB (N2) non-squamous non-small cell lung cancer (NSCLC) (AJCC 8th edition).
  • With Known KRAS gene mutation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →